8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 26, 2026·SEC
Material company update
Jan 27, 2026·SEC
Vivani Medical, Inc.(VANI)Earnings, Financials & Key Ratios
VANI•NASDAQ
Price updated Jun 19, 2026
AboutVivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.Show more
- Revenue$0
- EBITDA-$27M-11.8%
- Net Income-$27M-13.3%
- EPS (Diluted)-0.43
- ROE-159.62%-30.4%
VANI Key Insights
Vivani Medical, Inc. (VANI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Profits declining 23.5% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 13.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when VANI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VANI Price & Volume
Vivani Medical, Inc. (VANI) stock price & volume — 10-year historical chart
Loading chart...
VANI Growth Metrics
Vivani Medical, Inc. (VANI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-14.06%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM6.39%
Return on Capital
10 Years-249.03%
5 Years-143.06%
3 Years-69.92%
Last Year-80.61%
VANI Recent Earnings
Vivani Medical, Inc. (VANI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.08+0.0%
$0.08
Rev
—
—
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.09+0.0%
$0.09
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.11+8.3%
$0.12
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.12-20.0%
$0.10
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.08vs $0.08+0.0% | — |
| Q2 2026 | Mar 26, 2026 | $0.09vs $0.09+0.0% | — |
| Q4 2025 | Nov 13, 2025 | $0.11vs $0.12+8.3% | — |
| Q3 2025 | Aug 13, 2025 | $0.12vs $0.10-20.0% | — |
Based on last 12 quarters of dataView full earnings history →
VANI Peer Comparison
Vivani Medical, Inc. (VANI) competitors in Neuromodulation and neuro devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 GKOS | 7.65B | 130.68 | -39.84 | 32.33% | -34.34% | -26.46% | 0.21 | |
 BRNS | 27.05M | 0.66 | -0.40 | -100% | -63.83% | 0.15 | ||
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 TNDM | 1.05B | 15.30 | -5.03 | 7.93% | -9.2% | -68.29% | 2.86 | |
 NVO | 191.93B | 43.19 | 12.18 | 6.43% | 37.2% | 66.36% | 0.67 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 |
Compare VANI vs Peers
Vivani Medical, Inc. (VANI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VANI Income Statement
Vivani Medical, Inc. (VANI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 7.96M | 6.9M | 3.38M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | 99.85% | -13.41% | -51% | -100% | - | - | - | - | - | - |
Cost of Goods Sold | 7.75M | 4.89M | 2.15M | 0 | 0 | 0 | 357K | 0 | 424K | 130K |
COGS % of Revenue | 97.35% | 70.88% | 63.69% | - | - | - | - | - | - | - |
Gross Profit | 211K▲ 0% | 2.01M▲ 851.7% | 1.23M▼ 38.9% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | -357K▲ 0% | 0▲ 100.0% | -424K▲ 0% | -130K▲ 0% |
Gross Margin % | 2.65% | 29.12% | 36.31% | - | - | - | - | - | - | - |
Gross Profit Growth % | 103.93% | 851.66% | -38.89% | -100% | - | - | - | 100% | - | - |
Operating Expenses | 28.92M | 36.83M | 31.82M | 9.24M | 13.32M | 21.24M | 26.61M | 24.68M | 27.13M | 27.68M |
OpEx % of Revenue | 363.13% | 534.12% | 941.82% | - | - | - | - | - | - | - |
Selling, General & Admin | 23.56M | 26.63M | 15.33M | 2.38M | 2.32M | 5.37M | 10M | 8.93M | 9.43M | 9.52M |
SG&A % of Revenue | 295.87% | 386.14% | 453.6% | - | - | - | - | - | - | - |
Research & Development | 7.99M | 10.21M | 16.5M | 6.87M | 11M | 14.17M | 16.97M | 15.74M | 18.13M | 18.17M |
R&D % of Revenue | 100.36% | 147.98% | 488.22% | - | - | - | - | - | - | - |
Other Operating Expenses | -2.64M | 0 | 0 | 0 | 0 | 1.7M | -357K | 0 | -424K | 0 |
Operating Income | -28.71M▲ 0% | -34.83M▼ 21.3% | -30.6M▲ 12.1% | -9.24M▲ 69.8% | -13.32M▼ 44.1% | -21.24M▼ 59.4% | -26.96M▼ 26.9% | -24.68M▲ 8.5% | -27.56M▼ 11.7% | -27.81M▲ 0% |
Operating Margin % | -360.48% | -505% | -905.5% | - | - | - | - | - | - | - |
Operating Income Growth % | 13.55% | -21.3% | 12.14% | 69.79% | -44.14% | -59.43% | -26.95% | 8.49% | -11.67% | - |
EBITDA | -28.25M | -34.39M | -30.18M | -8.89M | -12.98M | -20.86M | -26.61M | -24.28M | -27.13M | -27.36M |
EBITDA Margin % | -354.75% | -498.69% | -893.25% | - | - | - | - | - | - | - |
EBITDA Growth % | 13.81% | -21.73% | 12.23% | 70.55% | -46% | -60.73% | -27.56% | 8.76% | -11.76% | -11.21% |
D&A (Non-Cash Add-back) | 457K | 435K | 414K | 354K | 345K | 381K | 357K | 400K | 424K | 452K |
EBIT | -28.52M | -35.09M | -33.59M | -9.24M | -13.32M | -19.54M | -25.65M | -24.68M | -27.56M | -27.81M |
Net Interest Income | 0 | 0 | 362K | 16K | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Income | 93K | 86K | 362K | 16K | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 193K | -269K | -3M | -36K | 550K | 7.35M | 1.31M | 1.19M | 947K | 727K |
Pretax Income | -28.52M▲ 0% | -35.09M▼ 23.1% | -33.59M▲ 4.3% | -9.28M▲ 72.4% | -12.77M▼ 37.7% | -13.89M▼ 8.7% | -25.65M▼ 84.7% | -23.49M▲ 8.4% | -26.61M▼ 13.3% | -27.09M▲ 0% |
Pretax Margin % | -358.06% | -508.9% | -994.14% | - | - | - | - | - | - | - |
Income Tax | 93K | 86K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.33% | -0.25% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -28.52M▲ 0% | -35.09M▼ 23.1% | -33.59M▲ 4.3% | -9.28M▲ 72.4% | -12.77M▼ 37.7% | -13.89M▼ 8.7% | -25.65M▼ 84.7% | -23.49M▲ 8.4% | -26.61M▼ 13.3% | -27.09M▲ 0% |
Net Margin % | -358.06% | -508.9% | -994.14% | - | - | - | - | - | - | - |
Net Income Growth % | 14.05% | -23.07% | 4.28% | 72.38% | -37.65% | -8.74% | -84.69% | 8.44% | -13.3% | -14.06% |
Net Income (Continuing) | -28.52M | -35.09M | -33.59M | -9.28M | -12.77M | -13.89M | -25.65M | -23.49M | -26.61M | -27.09M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -4.01▲ 0% | -4.08▼ 1.7% | -2.15▲ 47.3% | -0.33▲ 84.7% | -0.33▲ 0.0% | -0.17▲ 48.5% | -0.50▼ 194.1% | -0.43▲ 14.0% | -0.43▲ 0.0% | -0.33▲ 0% |
EPS Growth % | 33.06% | -1.75% | 47.3% | 84.65% | 0% | 48.48% | -194.12% | 14% | 0% | 6.39% |
EPS (Basic) | -4.01 | -4.08 | -2.15 | -0.33 | -0.33 | -0.17 | -0.50 | -0.43 | -0.43 | - |
Diluted Shares Outstanding | 7.11M | 8.6M | 15.61M | 28.11M | 36.25M | 38.24M | 50.85M | 54.98M | 62.39M | 81.27M |
Basic Shares Outstanding | 7.11M | 8.6M | 15.61M | 28.11M | 36.25M | 38.24M | 50.85M | 54.98M | 62.39M | 81.27M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
VANI Balance Sheet
Vivani Medical, Inc. (VANI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 13.16M | 9.62M | 13.11M | 2.43M | 2.47M | 47.53M | 23.06M | 20.44M | 17.9M | 21.55M |
Cash & Short-Term Investments | 7.84M | 4.47M | 11.33M | 2.08M | 2.18M | 45.08M | 20.65M | 18.35M | 16.23M | 19.75M |
Cash Only | 604K | 4.47M | 11.33M | 2.08M | 2.18M | 45.08M | 20.65M | 18.35M | 16.23M | 19.75M |
Short-Term Investments | 7.24M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 1.83M | 504K | 455K | 0 | 0 | 0 | 0 | 253K | 654K | 12K |
Days Sales Outstanding | 83.92 | 26.68 | 49.15 | - | - | - | - | - | - | - |
Inventory | 2.7M | 3.25M | 1.03M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 127.11 | 242.69 | 174.53 | - | - | - | - | - | - | - |
Other Current Assets | 795K | 1.4M | 299K | 0 | 0 | 0 | 2.41M | 1.84M | 1.01M | 1.79M |
Total Non-Current Assets | 1.33M | 1.06M | 3.49M | 2.79M | 2.98M | 3.6M | 22.73M | 21.12M | 21.5M | 20.8M |
Property, Plant & Equipment | 1.3M | 1.02M | 3.46M | 2.59M | 2.78M | 1.96M | 21.34M | 19.65M | 20.11M | 19.37M |
Fixed Asset Turnover | 6.13x | 6.73x | 0.98x | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1.34M | 1.34M | 1.34M | 2.68M |
Other Non-Current Assets | 33K | 37K | 25K | 200K | 200K | 1.64M | 52K | 131K | 48K | 1.44M |
Total Assets | 14.5M▲ 0% | 10.68M▼ 26.3% | 16.6M▲ 55.4% | 5.22M▼ 68.6% | 5.45M▲ 4.5% | 51.13M▲ 837.6% | 45.8M▼ 10.4% | 41.56M▼ 9.2% | 39.39M▼ 5.2% | 42.35M▲ 0% |
Asset Turnover | 0.55x | 0.65x | 0.20x | - | - | - | - | - | - | 0.00x |
Asset Growth % | -13.77% | -26.32% | 55.39% | -68.57% | 4.52% | 837.65% | -10.43% | -9.25% | -5.22% | -67.42% |
Total Current Liabilities | 6.62M | 7.6M | 6.96M | 2.19M | 2.09M | 6.82M | 5.72M | 5.99M | 6.6M | 6.78M |
Accounts Payable | 752K | 1.3M | 1.09M | 223K | 281K | 1.18M | 542K | 817K | 1.03M | 1.47M |
Days Payables Outstanding | 35.4 | 97.45 | 185.38 | - | - | - | 554.15 | - | 888.4 | 4K |
Short-Term Debt | 0 | 0 | 237K | 637K | 0 | 0 | 0 | 0 | 1.79M | 1.78M |
Deferred Revenue (Current) | 48K | 167K | 335K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3.2M | 3.44M | 2.6M | 0 | 0 | 385K | 396K | 343K | 3.78M | 3.53M |
Current Ratio | 1.99x | 1.27x | 1.88x | 1.11x | 1.18x | 6.97x | 4.03x | 3.41x | 2.71x | 3.18x |
Quick Ratio | 1.58x | 0.84x | 1.74x | 1.11x | 1.18x | 6.97x | 4.03x | 3.41x | 2.71x | 3.18x |
Cash Conversion Cycle | 175.63 | 171.91 | 38.29 | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 2.37M | 1.08M | 902K | 0 | 19.31M | 17.96M | 17.06M | 16.49M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17.06M | 16.49M |
Capital Lease Obligations | 0 | 0 | 2.37M | 1.08M | 902K | 0 | 19.31M | 17.96M | 0 | 17.28M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 4K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6.62M | 7.6M | 9.32M | 3.27M | 2.99M | 6.82M | 25.04M | 23.95M | 23.66M | 23.27M |
Total Debt | 0 | 0 | 2.6M | 2.47M | 1.81M | 955K | 20.7M | 19.31M | 18.86M | 18.27M |
Net Debt | -604K | -4.47M | -8.72M | 386K | -366K | -44.12M | 42K | 961K | 2.62M | -1.47M |
Debt / Equity | - | - | 0.36x | 1.27x | 0.74x | 0.02x | 1.00x | 1.10x | 1.20x | 0.96x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.67x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.05x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 7.88M▲ 0% | 3.08M▼ 60.9% | 7.28M▲ 135.9% | 1.95M▼ 73.2% | 2.46M▲ 26.4% | 44.31M▲ 1697.5% | 20.76M▼ 53.1% | 17.61M▼ 15.2% | 15.73M▼ 10.7% | 19.09M▲ 0% |
Equity Growth % | -29.31% | -60.87% | 135.89% | -73.2% | 26.41% | 1697.48% | -53.14% | -15.18% | -10.68% | -118.74% |
Book Value per Share | 1.11 | 0.36 | 0.47 | 0.07 | 0.07 | 1.16 | 0.41 | 0.32 | 0.25 | 0.23 |
Total Shareholders' Equity | 7.88M | 3.08M | 7.28M | 1.95M | 2.46M | 44.31M | 20.76M | 17.61M | 15.73M | 19.09M |
Common Stock | 202.16M | 229.02M | 264.01M | 43.03M | 54.65M | 5K | 5K | 6K | 8K | 8K |
Retained Earnings | -234.38M | -269.47M | -304.78M | -46.12M | -58.9M | -72.79M | -98.44M | -121.92M | -148.53M | -155.31M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -572K | -575K | -562K | -448K | 0 | 35K | 140K | 48K | 30K | 32K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VANI Cash Flow Statement
Vivani Medical, Inc. (VANI) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -23.95M | -29.81M | -27.63M | -7.62M | -10.95M | -18.79M | -23.7M | -20.79M | -24.32M | -25.35M |
Operating CF Margin % | -300.69% | -432.28% | -817.67% | - | - | - | - | - | - | - |
Operating CF Growth % | 4.48% | -24.48% | 7.32% | 72.42% | -43.73% | -71.56% | -26.15% | 12.29% | -17% | -74.59% |
Net Income | -28.52M | -35.09M | -33.59M | -9.28M | -12.77M | -13.89M | -25.65M | -23.49M | -26.61M | -27.09M |
Depreciation & Amortization | 457K | 435K | 414K | 354K | 345K | 381K | 357K | 400K | 424K | 452K |
Stock-Based Compensation | 3.78M | 0 | 0 | 1.04M | 1.67M | 1.3M | 1.86M | 1.61M | 1.48M | 1.13M |
Deferred Taxes | 0 | 0 | -4.26M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -324K | 4.7M | 9.78M | 123K | -627K | -6.91M | 1.02M | 336K | 152K | 437K |
Working Capital Changes | 3.31M | 425K | 37K | 146K | 436K | 338K | -1.29M | 354K | 229K | -289K |
Change in Receivables | -1.41M | 1.22M | 48K | 0 | 0 | 0 | 0 | 0 | -401K | -522K |
Change in Inventory | 3.87M | -1.18M | -347K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -419K | 554K | -213K | -18K | 13K | -1.94M | -602K | 248K | -222K | 432K |
Cash from Investing | 2.84M | -163K | -493K | -150K | -572K | -338K | -887K | -556K | -1.17M | -1.17M |
Capital Expenditures | -265K | -163K | -493K | -150K | -572K | -338K | -887K | -556K | -1.17M | -1.17M |
CapEx % of Revenue | 3.33% | 2.36% | 14.59% | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 21.17M | 26.6M | 34.99M | 9.19M | 11.62M | 63.39M | 133K | 19.05M | 23.27M | 33.16M |
Debt Issued (Net) | 0 | 0 | 0 | 637K | 0 | 8M | 0 | 19.05M | 11K | 141K |
Equity Issued (Net) | 21.17M | 26.6M | 34.99M | 8.55M | 11.62M | 16K | 133K | 18.82M | 23.26M | 33.08M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -28K | 0 |
Other Financing | 0 | 0 | 0 | 0 | 0 | 55.37M | 0 | -18.82M | 0 | -67K |
Net Change in Cash | -3.04M▲ 0% | -3.37M▼ 10.9% | 6.86M▲ 303.6% | 1.42M▼ 79.3% | 97K▼ 93.2% | 44.26M▲ 45533.0% | -24.45M▼ 155.2% | -2.3M▲ 90.6% | -2.12M▲ 7.9% | 6.74M▲ 0% |
Free Cash Flow | -24.21M▲ 0% | -29.97M▼ 23.8% | -28.12M▲ 6.2% | -7.77M▲ 72.4% | -11.52M▼ 48.3% | -19.13M▼ 66.0% | -24.59M▼ 28.6% | -21.34M▲ 13.2% | -25.49M▼ 19.4% | -26.52M▲ 0% |
FCF Margin % | -304.02% | -434.64% | -832.26% | - | - | - | - | - | - | - |
FCF Growth % | 5.27% | -23.79% | 6.18% | 72.37% | -48.32% | -65.97% | -28.55% | 13.19% | -19.45% | -21.58% |
FCF per Share | -3.41 | -3.49 | -1.80 | -0.28 | -0.32 | -0.50 | -0.48 | -0.39 | -0.41 | -0.33 |
FCF Conversion (FCF/Net Income) | 0.84x | 0.85x | 0.82x | 0.82x | 0.86x | 1.35x | 0.92x | 0.89x | 0.91x | 0.98x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 1K | 1K | 0 | 1K | 2K | 0 | 0 |
VANI Key Ratios
Vivani Medical, Inc. (VANI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -299.66% | -640.05% | -648.56% | -201.17% | -578.62% | -59.39% | -78.85% | -122.42% | -159.62% | -264.04% |
Return on Invested Capital (ROIC) | -570.15% | -886.73% | - | -1564.84% | -450.61% | -1393.77% | -192.7% | -94.01% | -111.94% | -119.77% |
Gross Margin | 2.65% | 29.12% | 36.31% | - | - | - | - | - | - | - |
Net Margin | -358.06% | -508.9% | -994.14% | - | - | - | - | - | - | - |
Debt / Equity | - | - | 0.36x | 1.27x | 0.74x | 0.02x | 1.00x | 1.10x | 1.20x | 0.96x |
FCF Conversion | 0.84x | 0.85x | 0.82x | 0.82x | 0.86x | 1.35x | 0.92x | 0.89x | 0.91x | 0.98x |
Revenue Growth | 99.85% | -13.41% | -51% | -100% | - | - | - | - | - | - |
Related:VANI Dividend History·VANI Revenue History·VANI Price History·VANI P/E History·VANI Financial Ratios·VANI Institutional Holders
VANI SEC Filings & Documents
Vivani Medical, Inc. (VANI) SEC filings — annual & quarterly reports (10-K, 10-Q)
VANI Frequently Asked Questions
Vivani Medical, Inc. (VANI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Vivani Medical, Inc. (VANI) grew revenue by 0.0% over the past year. Growth has been modest.
Vivani Medical, Inc. (VANI) reported a net loss of $27.1M for fiscal year 2025.
Dividend & Returns
Vivani Medical, Inc. (VANI) has a return on equity (ROE) of -159.6%. Negative ROE indicates the company is unprofitable.
Vivani Medical, Inc. (VANI) had negative free cash flow of $26.5M in fiscal year 2025, likely due to heavy capital investments.